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Calcium channel blockers enhance sac shrinkage
after endovascular aneurysm repair
Marc A. Bailey, MRCS,a,b Soroush Sohrabi, PhD,a,b Karen Flood, FRCR,c Kathryn J. Griffin, MRCS,a,b
S. Tawqeer Rashid, PhD,a,b Anne B. Johnson,b Paul D. Baxter, PhD,d Jai V. Patel, FRCR,c and
D. Julian A. Scott, MD,a,b Leeds, United Kingdom
Objective: Sac shrinkage is a surrogate marker of success after endovascular aneurysm repair (EVAR). We set out to
determine if any common cardioprotective medications had a beneficial effect on sac shrinkage.
Methods: This retrospective observational study took place at Leeds Vascular Institute, a tertiary vascular unit in the
Northern United Kingdom. The cohort comprised 149 patients undergoing EVAR between January 1, 2005, and
December 31, 2008. Medication use was recorded at intervention (verified at study completion in 33 patients), and
patients were monitored for 2 years. The main outcome measures were the effect of medication on sac shrinkage as
determined by percentage change in maximal idealized cross-sectional area of the aneurysm at 1 month, 6 months, 1 year,
and 2 years by linear regression model, in addition to 2-year endoleak and death rates determined by a binary logistic
regression model.
Results: After exclusions, 112 patients, who were a median age of 78 years (interquartile range, 78-83 years),
remained for analysis. The median Glasgow Aneurysm Score was 85 (interquartile range, 79-92). At 2 years,
mortality was 13.4%, endoleak developed in 37.5%, and significant endoleak developed in 14.3%. Patients taking a
calcium channel blocker had enhanced sac shrinkage, compared with those not taking a calcium channel blocker, by
6.6% at 6 months (3.0% to 16.3%, P  .09), 12.3% at 1 year (2.9% to 21.7%, P  .008), and 13.1% at 2 years
(0.005% to 26.2%, P  .007) independent of other medication use, graft type, endoleak development, or death.
Conclusions: Enhanced sac shrinkage occurred after EVAR in patients taking calcium channel blockers. This warrants
further study in other centers and at the molecular level. ( J Vasc Surg 2012;55:1593-9.)
y
e
t
s
w
i
z
a
r
w
p
t
t
a
p
b
m
H
c
i
t
i
(
h
W
dAbdominal aortic aneurysm (AAA) is present in 4% to
9% of men aged 65 years.1,2 Prophylactic repair is
offered once the annual risk of rupture outweighs the
risks associated with surgery.3 Traditionally, repair has
been with open surgery; however, endovascular aneu-
rysm repair (EVAR) is a minimally invasive alternative
with lower perioperative morbidity and mortality.4,5 De-
spite these short-term advantages, EVAR is significantly
less durable than open repair in the long-term, with
30% of patients requiring reintervention over 10
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doi:10.1016/j.jvs.2011.12.075ears.6,7 Endograft migration or the development of
ndoleaks allows sac repressurization with ongoing rup-
ure risk. As a consequence, patients require prolonged
erial imaging after EVAR to identify markers of risk that
arrant further investigation and treatment.
The pathogenesis of AAA appears to be driven by
nflammation8 and overproduction of proteolytic en-
ymes, specifically matrix metalloproteinases (MMP)-2
nd MMP-9.9-11 A critical difference between traditional
epair and EVAR is the persistence of the unaltered sac
ith its intraluminal thrombus, a potential source of
roteolysis12 and MMP-9 potentiation,13 allowing con-
inuation of the inflammatory process after the interven-
ion. Ongoing matrix degradation could possibly lead to
lterations in the post-EVAR sac with an effect on the
roximal seal. An association has been demonstrated
etween elevated MMP-9 levels and endoleak develop-
ent.14 Little work has been undertaken in this area, but
ackman et al15 showed that post-EVAR sac shrinkage
ould be enhanced with doxycycline, a potent MMP-9
nhibitor.
The 3-hydroxy-3 methyl-glutaryl coenzyme A reduc-
ase inhibitors (statins),16 angiotensin-converting enzyme
nhibitors (ACEI),17 and calcium channel blockers
CCB)18,19 all downregulateMMP production in vitro and
ave been linked with reduced AAA growth rates in vivo.
e set out to establish if these commonly prescribed car-
ioprotective medical therapies had an effect on sac shrink-
ge (a surrogate marker of success), endoleak development,
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undergoing EVAR.
METHODS
Patients. The study included the 149 patients who
underwent EVAR at a single tertiary vascular center in the
Northern United Kingdom between January 2005 and
December 2008. Patients were entered into a prospective
database and the case notes were retrospectively reviewed.
Cardiovascular risk factors and medical history were ob-
tained at the time of operation from the medical notes.
Systolic blood pressure (SBP) at the preassessment visit was
recorded. Medication use at the time of EVAR was re-
corded from themedical case notes.Medication history was
confirmed at the end of the study period (March 2011) in a
subset of 33 participants (29%) at visits to the outpatient
department. Patients were placed in subgroups according
to medication use, and to serve as markers of comorbidity
in each subgroup, the American Society of Anesthesiolo-
gists (ASA) score was recorded from the anesthetic records,
and the Glasgow Aneurysm Score (GAS [age in years]
[7 for myocardial disease]  [10 for cerebrovascular dis-
ease]  [14 for renal disease])20 was calculated for each
patient. Graft type was confirmed from the operative notes.
Patients were monitored for 2 years after EVAR for sac
size, endoleak development, and death. Significant en-
doleak was defined as any type I, III, and V endoleak or a
type II endoleak with evidence of sac expansion. Two-year
mortality data were gathered from case notes and verified
using the hospital Patient Administration System (National
Health Service, Connecting for Health, Leeds, UK). Pa-
tients with unavailable, incomplete, ormissing case notes or
who underwent preoperative evaluation or radiologic sur-
veillance at another institution were excluded.
Aneurysm measurements. All AAA imaging for each
patient was retrieved from the hospital Picture Archiving
and Communication System, and the maximal anteropos-
terior (AP) and transverse diameters, from inner wall to
inner wall, were measured by one radiologist (K.F.) who
was blind to the patients’ clinical and pharmacologic pa-
rameters. Measurements were taken from the preoperative
scan from which EVAR was planned and at standardized
follow-up intervals for our department: 1 month, 6
months, 1 year, and 2 years after EVAR. Isolated missing
scans were excluded from the analysis.
All patients underwent preoperative computed tomog-
raphy (CT) scanning and at least one further surveillance
scan. Patients were initially monitored with serial CT scans.
Our departmental protocol changed in 2006, after which
patients received a CT scan at 1 month and 2 years, with
ultrasound scans (USS) for interim scans unless sac expan-
sion was detected, which prompted further evaluation with
CT. Themaximal AP and transverse diameters were used to
calculate idealized maximal cross-sectional areas by using
the formula [ab]. The percentage change in idealized
maximal cross-sectional area was calculated at 1 month, 6
months, 1 year, and 2 years from the pre-EVAR images so
that both AP and transverse diameters were included and to hormalize the data to the AAA size at intervention. Analysis
as undertaken in subgroups stratified bymedication use at
he time of EVAR.
Power. The study was powered at 80% to detect a
ifference in sac shrink of 10% among subgroups with 95%
onfidence. We presumed for this calculation that approx-
mately 80% of patients would have available imaging at
ssessment to account for missed appointments and deaths.
ased on previously published work,21-23 we determined
hat a 10% difference would be clinically relevant and large
nough to overcome the variability introduced by the un-
voidable mixture of CT and USS surveillance in the study
opulation.
Statistical analysis. Statistical analysis was undertaken
sing SPSS 19 software (SPSS Inc, Chicago, Ill) in the
ubgroups as outlined above. Normality of the data was
ssessed using the Shapiro-Wilk test. Continuous variables
ere compared using the Mann-Whitney U test and cate-
orical variables using the 2 test. False discovery rate
djustment24 was used to correct for multiple testing. The
ignificance of differences in sac shrinkage (the mean per-
entage difference in idealized maximal cross-sectional area
rom pre-EVAR imaging) among subgroups for each med-
cation type at the standardized time intervals was assessed
sing a linear regression model. A separate regression line
as used for each follow-up period, including all medica-
ions (statins, -blockers, ACEI, CCB, aspirin, warfarin,
nd diuretic) and graft type in addition to endoleak devel-
pment and death at 2 years. A binary logistic regression
odel was used to determine factors associated with sac
xpansion at each interval, including medications, graft
ype, endoleak development, and death. Sac shrinkage is
resented as mean percentage reduction with 95% confi-
ence intervals and multivariate P value.
ESULTS
atient demographics
Of 149 patients, 30 had missing, unavailable or
ncomplete case notes, four underwent preprocedural
maging at another institution, which was not available
or review, and three patients underwent radiologic sur-
eillance elsewhere. This left 112 patients for analysis
Fig 1), 89.3% men and 10.7% women, who were a
edian age of 78 years (interquartile range [IQR],
3-83 years). The median GAS was 85 (IQR, 79-92),
ith a median ASA of 3 (IQR, 2-3). Median AAA size at
ntervention was 62 mm (IQR, 57-70 mm). Median SBP
as 134 mm Hg (IQR, 122-134 mm Hg).
Devices. Overall, 80 (71.4%) Talent devices (Medtronic,
inneapolis, Minn), 21 (18.8%) Zenith devices (Cook
edical Inc, Bloomington, Ind), six (5.4%) Excluder de-
ices (W. L. Gore and Assoc, Flagstaff, Ariz), and five
4.5%) other devices were deployed.
Medication history. Medical therapy at intervention
ncluded statin drugs in 73.2% of patients, a -blocker in
6.6%, ACEI in 31.2%, and CCB in 18.8%. Medication
istory was verified in 33 patients in March 2011, and no
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ing by medication in the study.
All-cause mortality. At 2 years, 15 patients had died,
for an all-cause mortality rate of (13.4%). Two deaths
(1.8%) were aneurysm-related (rupture).
Endoleak and sac shrinkage. At follow-up, 42 pa-
tients (37.5%) had developed an endoleak. Of these, 16
(14.3%) were considered to be significant (five type I, nine
type II with expanding sack requiring intervention, and two
type III). A summary is provided in the Table. A total of 89
imaging studies were available at 1 month, 89 were avail-
able at 6 months, 88 at 1 year, and 84 at 2 years. These
images showed that 52.8% of patients had a shrinking
aneurysm sac at 1 month, 71.9% at 6 months, 82.9% at 1
year, and 86.9% at 2 years.
Pharmacotherapy
Statins. There were 81 patients taking a statin and 31
not taking a statin. Groups were similar in age, sex, GAS,
ASA score, AAA size at intervention, SBP, other medica-
tion usage, and graft type. There was no significant differ-
ence in sac size reduction, endoleak development, or death
between the groups (Fig 2, A).
-blockers. There were 41 patients taking -blockers
and 71 not taking -blockers. Groups were well matched
for age, sex, ASA score, AAA size, SBP, and other medical
therapy. There was no significant difference in sac shrink-
age, endoleak development, or mortality between the
groups (Fig 2, B).
Angiotensin converting enzyme inhibitors. There
were 35 patients taking an ACEI and 77 not taking an
ACEI. Groups were comparable in age, sex, GAS, ASA
score, AAA size at intervention, SBP, graft type, and other
medication use. There was no significant difference in sac
size reduction, endoleak development, or death between
patients who were and were not taking an ACEI (Fig 2,C).
Calcium channel blockers. There were 21 patients
taking a CCB and 91 not taking a CCB. Age, sex, GAS,
ASA score, SBP, and AAA size did not differ significantly
between the groups (Table). The mean difference in per-
All EVARs 2005-2008 
n = 149 
Patients available for analysis 
n = 112 
Fig 1. Flow chart demonstrates the inclusion of patient
cular aneurysm repair.centage sac size reduction was 0.03% (5.2% to 5.1%, i .91) at 1 month, 6.6% (3.0% to 16.3%, P .09) at 6
onths, 12.3% (2.9% to 21.7%, P  .008) at 1 year, and
3.1% (0.005% to 26.2%, P  .007) at 2 years (Fig 2, D).
here was no significant difference in significant endoleak
evelopment (9.5% [one type I and one type II with
xpanding sac] vs 15.4% [four type I, eight type II with
xpanding sac, and two type III], P  .7) or death.
ISCUSSION
EVAR has significant short-term advantages over
pen repair but is associated with a higher rate of rein-
ervention in the follow-up period.6,7 In the case of
VAR, the aneurysm sac persists after the intervention
nd fills with thrombus, which may act as a source of
ngoing inflammation with the potential to alter neck
orphology and lead to endoleak development, sac re-
ressurization, and potentially, rupture. Sac shrinkage
n serial imaging is taken as a surrogatemarker of success, but
ittle is known about the mechanisms behind this phenomenon.
he potential of pharmacotherapies to enhance sac shrinkage
fter EVAR has received relatively little attention in the liter-
ture, with the only work to date reporting on the potential
eneficial effects of doxycycline15 and the detrimental ef-
ects of aspirin25 or warfarin,26 despite considerable interest
n pharmacotherapy to attenuate aneurysm growth before
ntervention.
We have demonstrated enhanced sac shrinkage up to 2
ears after EVAR in patients taking CCB, independent of
ther medication use, endoprosthesis type, the presence of
ndoleak, and death. ACEI, statins, and -blockers did not
ppear to have any significant affect. As in the study by
ackmann et al,15 adverse events (significant endoleak and
neurysm-related death) were rare in our series, and conse-
uently, our observational study lacked enough power to
lucidate if the enhanced sac shrinkage conferred a reduced
ncidence of endoleak or lower mortality. Not enough
atients were in the CCB group to demonstrate a dose-
esponse effect or identify a specific CCB to be advanta-
eous. Notwithstanding, the pattern of enhanced sac
hrinkage with specific medication use remains an interest-
issing, unavailable or incomplete case notes 
 = 30) 
adiological surveillance at another institution 
 = 3) 
VAR planning CT at another institution 
 = 4)  
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macologic sac manipulation confers true clinical benefit as
measured by reduced endoleak development and improved
aneurysm-related mortality.
Previous work has demonstrated that endoleak devel-
opment after EVARwas associated with elevated peripheral
levels of MMP-9.15 Because statins10 and CCB27 can re-
duce MMP-9 levels, we initially hypothesized that MMP
modulation might affect sac shrinkage after EVAR. How-
ever, our observation that CCB enhanced sac shrinkage
independent of other MMP-modulating agents suggests
the true explanation is more complex.
Tumor necrosis factor-	 (TNF-	) is a proinflammatory
cytokine that operates upstream of MMP production in the
inflammatory cascade. TNF-	 is upregulated in small but not
large AAAs,28 and TNF-	/ mice are resistant to experi-
mental AAA formation.29 Taken together, these studies sug-
gest an important role for TNF-	 in the development of AAA
but a lesser role once the AAA is established. The CCB
nifedipine inhibits TNF-	–induced endothelial cell apoptosis
and activation by blocking nicotinamide adenine dinucleotide
phosphate hydrogen oxidase-mediated reactive oxygen spe-
cies generation.30 After EVAR, there is a proinflammatory
environment, elevated C-reactive protein, interleukins, and
body temperature,31 all of which have been linked to TNF-
	.32 CCBs may therefore modulate the post-EVAR environ-
ment by downregulationof the inflammatory response.This is
an interesting area for further study at the molecular level.
The patients in our study were of similar age and sex
distribution to the patients of the Comparison of Endovas-
cular Aneurysm Repair with Open Repair in Patients with
Abdominal Aortic Aneurysm (EVAR) 1 and Dutch Ran-
domised Endovascular Aneurysm Management (DREAM)
Table. Demographics and covariates of the study populati
Variablea Total
Patients, No. 112
Age, years 78 (73-83)
Male sex 89.3
GAS 85 (79-92)
AAA size pre-EVAR, mm 62 (57-70)
SBP, mm Hgb 134 (122-134)
Graft
Zenith 18.8
Talent 71.4
Gore 5.4
Other 4.5
Deathc 13.4
Endoleakc 37.5
Significant endoleakd 14.3
AAA, Abdominal aortic aneurysm; ACEI, angiotensin converting enzyme
GAS, Glasgow Aneurysm Score; SBP, systolic blood pressure; Statin, 3-hyd
aContinuous data are presented as median (interquartile range) and categor
bBlood pressure measurement at the preassessment clinic visit.
cDeath and endoleak development at 2 years.
dAny type I, III, IV, or V leak and a type II leak with an expanding sac by 2trials, with similar AAA size at intervention. TheGAS of our tatient group was higher than that reported in theDREAM
tudy,33 and this perhaps explains the higher statin and
spirin usage in our patients compared with those in the
VAR I andDREAM trials. Our rates of reintervention and
neurysm-related mortality are similar to these published
eports; however, our all-cause mortality rate is higher. We
elate this to the greater comorbidity, as reflected by a
igher GAS in our patient population.
Our single-center retrospective observational study has
number of limitations. A change in our local EVAR
urveillance protocol necessitated the inclusion of both CT
nd USS in our sac measurement data. In the post-EVAR
nvironment, USS and CT measurements are closely cor-
elated,21 but there are absolute differences of 4 to 5 mm
etween modalities.22,23 We have found good agreement
etween USS and CT measurement in our own unit.34
urthermore, the 2-year scan, which shows the greatest
ifferences in sac shrinkage between CCB and controls, was
CT scan in all cases.
We presented sac shrinkage as a percentage change in
dealized cross-sectional area for two reasons: (1) to nor-
alize the data to the starting aneurysm size, and (2) to
ake into account both the AP and transverse measure-
ents. We felt it was important to include both measure-
ents in the analysis, because a sac that is static in the AP
lane but shrinking in the transverse plane is still shrinking
verall. Volumetric analysis may be a useful future adjunct
n this area that requires further investigation but requires
T imaging for all follow-up scans.
In this study, we have only presented 2 years of follow-
p. An important next step will be to re-evaluate the
elationship when longer-term follow-up data are available
verall and stratified by medication use
Statin
Yes No P
82 30
(72-82.75) 80 (74.25-83.75) .6
90.2 86.7 .7
(79.25-91.75) 85 (76.75-91.75) .8
(57-67.25) 65 (60-71) .2
(121-149) 135 (124.5-157) .7
20.7 13.3 .7
70.7 73.3 .7
4.9 6.7 .7
3.6 6.7 .7
12.2 16.7 .7
34.1 26.6 .7
13.4 16.7 .7
tor; CCB, calcium channel blocker; EVAR, endovascular aneurysm repair;
methyl-glutaryl coenzyme A reductase inhibitors.
as number or percentage.
.on o
78
85
60.5
134
inhibi
roxy-3
ic datao determine if the effect persists.
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Volume 55, Number 6 Bailey et al 1597Fig 2. Bar graphs demonstrate the mean percentage sac shrinkage from pre-endovascular aneurysm repair (EVAR)
imaging, at 1 month, 6 months, 1 year, and 2 years after EVAR for (A) statins, (B) -blockers, (C) angiotensin-
converting enzyme (ACE) inhibitors, and (D) calcium channel blockers. The error bars represent the standard error.Table. Continued
-blocker ACEI CCB
Yes No P Yes No P Yes No P
41 71 35 77 21 91
78 (72-82) 79 (74-83) .7 78.5 (74-83) 78.5 (74-83) .7 77 (68-82) 79 (74-83) .7
85.4 91.5 .4 85.7 92.2 .7 90.4 89 .7
88 (83-92) 83 (76-91) .8 85 (79-92) 85.5 (78.25-92.75) .7 86 (77-93) 85 (79-92) .9
59.5 (56-70) 63 (58-70) .9 62 (57-69.5) 64 (58.5-70) .1 62 (58-61) 62 (57-70) .7
135 (125-150) 134 (121-150) .7 134 (120-150) 134 (123.5-148.5) .9 145 (127-150) 133 (121-148) .6
22 16.9 .7 20 18.2 .7 16.6 18.7 .7
70.7 71.8 .7 80 67.5 .6 66.6 75.5 .7
2.4 7 .7 0 7.8 .6 9.5 4.4 .7
4.9 4.2 .6 0 6.5 .6 4.8 4.4 .7
12.2 14.1 .7 17.1 11.7 .7 14.3 13.2 .7
26.8 35.2 .7 25.7 35.1 .7 28.6 33.0 .7
12.2 15.5 .7 14.3 14.3 .7 9.5 15.4 .7**P 
 .01 on linear regression.
11
1
1
1
1
1
1
1
1
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at the intervention and was limited to overall drug class, not
to a specific subtype or dose. We were able to verify these
data at the end of the study for a subset of patients, but this
was not possible for all of our study population, which
means we were unable to completely correct for any cross-
over of patients between groups.
Further, we acknowledge that the polypharmacy of
patients makes it difficult to draw absolute conclusions on
the effect of a single drug class in isolation. This is a
limitation shared with much of the work on the effect of
medication on AAA growth rates. We also recognize that
only 19% of patients were taking a CCB and the possibility
that our observation represents a type I error. We, however,
believe it is important to study this observation in other
groups of patients who have undergone elective infrarenal
EVAR.
CONCLUSIONS
We present a novel clinical observation revealing en-
hanced sac shrinkage after EVAR in patients taking CCBs,
independent of other medication use, up to 2 years after
stent graft deployment. This warrants further study in other
centers because there are important implications for opti-
mizing medical management of patients after EVAR if this
effect can be confirmed in other patient populations.
We thank David Burtle, David Watson, and Janet
Woods for their help with data collection, verification, and
arrangement.
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